Modulators of Mortality Benefit From Peri-Angioplasty Adjunctive Tirofiban in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

CONCLUSIONS: Survival benefit from peri-angioplasty tirofiban therapy for STEMI was positively correlated with the Killip class. Tirofiban should be used cautiously in either underweight or overweight patients. The novel KBS used in this study can guide peri-angioplasty use of adjunctive tirofiban in patients with STEMI undergoing primary angioplasty. PMID: 33441492 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33441492?dopt=Abstract

Source: Circulation Journal - January 14, 2021 Category: Cardiology Authors: Yeh YT, Hsu JC, Liao PC, Li AH, Liu YH, Chen KC, Chuang W, Ke SR, Chiu YW, Wu YW Tags: Circ J Source Type: research